Market research
34LA.F Alpine Immune Sciences, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 20
- Dividend yield
- Not available
- Beta
- 0.97
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US02083G1004
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 20
- Dividend yield
- Not available
- Beta
- 0.97
About
About Alpine Immune Sciences, Inc
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington. As of May 20, 2024, Alpine Immune Sciences, Inc. operates as a subsidiary of Vertex Pharmaceuticals Incorporated.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 34LA.F discussion.
5 years, 4 months ago
Alpine Immune Sciences, Inc is currently in a long term downtrend where the price is trading 14.7% below its 200 day moving average.
From a valuation standpoint, the stock is 98.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 23.3.
Alpine Immune Sciences, Inc's total revenue rose by 538.3% to $6M since the same quarter in the previous year.
Its net income has dropped by 3.3% to $-6M since the same quarter in the previous year.
Finally, its free cash flow fell by 59.8% to $-10M since the same quarter in the previous year.
Based on the above factors, Alpine Immune Sciences, Inc gets an overall score of 2/5.